期刊文献+

水蛭治疗缺血性中风急性期随机对照试验的系统评价 被引量:10

A systematic review of hirudo for acute ischaemic stroke
下载PDF
导出
摘要 目的系统评价水蛭治疗缺血性中风急性期的疗效及安全性。方法检索水蛭治疗缺血性中风急性期随机对照试验文献,制定选择标准,筛选合格研究,应用Jadad评分法进行质量评价,运用异质性检验、Meta-分析、漏斗图分析、敏感性分析等方法统计相关数据。结果3项研究符合纳入标准,Jadad评分所有研究得分均低于3分,属低质量文献。Meta-分析结果显示,总有效率比较的相对危险度(RR)为1.17,99%的可信区间(CI)为(1.02,1.35);恶心呕吐发生率为5.41%,与空白对照比较,其RR(99%CI)为5.00(0.10,258.76)。结论Meta-分析结果显示水蛭具有改善缺血性中风急性期患者神经功能缺损状况的作用,且安全性较高。 Objective It is to evaluate systematically efficacy and safety of hirudo for acute ischaemic stroke. Methods Randomized controlled trails (RCTs) of hirudo for acute ischaemic stroke were identified, eligible studies were included, the methodological quality of inclusive trails was assessed by Jadad scale. Heterogeneity test, funnel plot analysis and sensitivity analysis were used to analyse data. Results Three RCTs were included, Jadad scale of all study were small than 3, with all trails of low methodological quality. Meta-analysis indicated that relative risk of overall effective rate of hirudo group was 1.17(99 % CI (1.02, 1. 35) ), that of control group was 5.00 (0.10, 258.76). Conclusion This systematic review shows that hirudo is effective and safety for acute ischaemic stroke.
作者 李可建
机构地区 山东中医药大学
出处 《现代中西医结合杂志》 CAS 2006年第17期2311-2312,2314,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
基金 国家中医药管理局资助课题(04-05LQ03)
关键词 水蛭 缺血性中风 急性期 随机对照试验 系统评价 hirudo acute ischaemic stroke randomized controlled trail systematic review
  • 相关文献

参考文献6

二级参考文献39

  • 1全国中风病协作组.中医中风病急症诊疗规范[J].中医急症通讯,1989,1(1):28-28.
  • 2[1]Markwardt F. The development of hirudin as an antithrombotic drug. Thrombosis Research, 1994,74( 1 ): 1 ~ 23.
  • 3[2]Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Heamost, 1991 ;66(1 ): 141 ~ 152.
  • 4[3]Vindigni V, Filippis VD, Zanotti G, et al. Probing the structure of hirudin from hirudinaria manillensis by limited proteolysis: isolation, characterization and thrombin-inhibitory properties of N-terminal fragments. Eur J Biochem,1994,226: 323 ~ 333.
  • 5[5]Nowak G, Markwardt F. Hirudin in disseminated intravascular coagulation.Haemostasis, 1991,21 (Supple 1 ): 142 ~ 148.
  • 6[6]Markwardt F, Kaiser B, Nowak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res, 1989,54(5) :377 ~ 388.
  • 7[7]Zawilska K, Zozulinska M, Turowiecka Z, et al. The effect of a long-acting recombinant hirudin (PEG-hirudin) on experimental disseminated intravascular coagulation (DIG) in rabbits. Thromb Res, 1993,69(3): 315 ~ 320.
  • 8[8]Doutremepuich C, Deharo E, Guyot M, et al. Antithrombotic activity of recombinant hirudin in the rat: a comparative study with heparin. Thromb Res,1989,54(5) :435 ~ 445.
  • 9[9]Talbot MD, Ambler I, Butler KD, et al. Recombinant desulphato-hirudin (CGP39393): anticoagulant and antithrombotic properties in vivo. Thromb Hemost, 1989,61 ( 1 ): 77 ~ 80.
  • 10[10]Bara L, Bloch MF, Sanana MM. A comparative study of recombinant hirudin and standard heparin in the Wessler modle. Thromb Res, 1992,68(2): 167~ 174.

共引文献65

同被引文献169

引证文献10

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部